A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.

Casey B Williams,Caitlin McMahon,Siraj M Ali,Mark Abramovitz,Kirstin A Williams,Jessica Klein, Heidi McKean, Roman Yelensky,Thomas J George, Julia A Elvin,Salil Soman,Doron Lipson,Juliann Chmielecki,Deborah Morosini,Vincent A Miller,Philip J Stephens,Jeffrey S Ross,Brian Leyland-Jones

ONCOTARGETS AND THERAPY（2015）

Cited 9|Views24
No score
Key words
oxaliplatin,colorectal adenocarcinoma,combination targeted therapy,BRAF mutations
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined